Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Bennu Bio Closes $15 Million Funding for T-Cell Therapies

publication date: Aug 15, 2022

Shanghai’s Bennu Biotherapeutics closed a $15 million Angel+ financing round to support its novel T-cell development programs. Founded in 2021, Bennu plans to take cell therapy beyond CAR-T drugs to include T cell types such as TIL, TCR-T and Treg. Although CAR-T has had great success in hematological tumors, it faces several clinical challenges overall. Bennu expects to aim its T cell drugs at solid tumor cancers and autoimmune diseases. The financing was led by INCE Capital with Life Science Park Innovation Fund and Witruth Capital participating. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022